Sector News

Deal-happy Actavis eyes Spain’s Almirall for European growth: Bloomberg

December 22, 2014
Life sciences
Actavis has been on quite the buying spree lately–and it may not be over yet.
 
Just one month after announcing a $66 billion pact to buy Allergan, the company is eyeing Spain’s Almirall as a way to boost its European growth, according to Bloomberg. The Barcelona drugmaker, which could fetch about €3 billion ($3.7 billion) in a deal, is reportedly one of several possible takeover targets on Actavis’ list.
 
With an Almirall deal would come products including Actikerall skin treatments and multiple sclerosis med Sativex, which would pad Actavis’ branded revenue overseas. Earlier this week, the company announced it would rejig its commercial ops, dividing sales and marketing three ways among international brands, branded pharma and Allergan medical.
 
Almirall, which recently sold off its respiratory business to AstraZeneca, may still decide to do some deals of its own, the news service notes–either before or instead of putting itself on the block. And the Gallardo family, which boasts a controlling stake in the company, may throw a wrench into Actavis’ plans if they decide not to sell. Almirall Chairman Jorge Gallardo and First Vice Chairman Antonio Gallardo own about 67% of the company’s stock, Bloomberg points out.
 
But if Actavis does land Almirall, it’ll be the latest pickup in a series that has launched the Dublin drugmaker into the ranks of Big Pharma’s biggest. Its Allergan buyout agreement followed recent buyouts of Forest Labs and Warner Chilcott, all of which should help put global sales in the realm of $23 billion next year.
 
Meanwhile, it’ll be up to dealmaker and CEO Brent Saunders–who has gone from the top spot at Bausch + Lomb to Forest and onto Actavis all within just over a year–to lead the combined company. And with a revenue goal of at least 8% growth a year–a high mark for drugmakers Actavis’ size, which usually manage top-line growth of a few percentage points a year–the young helmsman will have plenty on his plate.
 
By Carly Helfand
 

Related News

April 10, 2021

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Life sciences

Quita Highsmith, Genentech’s chief diversity officer, is helping the pharma double down on diversity and inclusion goals with a new 2025 plan. 

April 10, 2021

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Life sciences

Merck CEO Kenneth Frazier teamed up with former American Express executive Kenneth Chenault to protest a voting-rights law passed recently in Georgia.

April 10, 2021

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Life sciences

By bringing together big data and robotic procedures, the ultimate goal of the connected suite is to take some of the guesswork out of orthopedic medicine. 

Send this to a friend